RxDoctor Payments Data

Stephanie Eschete

Physician Assistant · New Orleans, LANPI 1275980906

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,142 of the $8,598 with a category attached, or 71.4%. It is spread thinly across 29 manufacturers, the largest accounting for just 23.3%. Reporting peaked in 2022 at $4,410 and has fallen 78.5% since, to $949 in 2025. Among physician assistant clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,598in general payments, 2019–2025

Across 160 payments — averaging $53.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • AbbVie$1K
  • Bristol Myers Squibb$1K
  • Gilead$764
  • Sanofi$337
  • Takeda Pharmaceuticals U.S.A., Inc.$297
  • plus $3K from 23 others

What the payments were for

  • Consulting fees$1,60319%
  • Travel & lodging$85210%
  • Food & beverage$6,14271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,598 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$577,426
StelaraUstekinumab18$445,151
InflectraInfliximab-Dyyb11$102,457
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates20$1,121
LoperamideLoperamide Hcl14$497
Omeprazole11$219
Sucralfate12$217
Pantoprazole Sodium26$129
Famotidine11$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$236$445,15118 claims
PfizerInflectra$259$102,45711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →